These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 8495120)
41. [Patients on anticoagulant therapy. Interpretation of a new test]. Benazzi A; Montebugnoli L Dent Cadmos; 1991 Jan; 59(1):66-70. PubMed ID: 1828046 [TBL] [Abstract][Full Text] [Related]
42. [Warfarin in the treatment of antiphospholipid syndrome]. Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075 [TBL] [Abstract][Full Text] [Related]
43. [A longitudinal study on left atrial thrombosis in patients with non-rheumatic atrial fibrillation treated with anticoagulants]. Scardi S; Mazzone C; Pandullo C; Goldstein D; Perkan A G Ital Cardiol; 1997 Oct; 27(10):1036-43. PubMed ID: 9359051 [TBL] [Abstract][Full Text] [Related]
50. How much do you know about anticoagulant therapy? Wimberley P; Wiggins N Nurs Manage; 2004 Feb; 35(2):46-7. PubMed ID: 14767234 [TBL] [Abstract][Full Text] [Related]
51. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Levy JH; Szlam F; Wolberg AS; Winkler A Clin Lab Med; 2014 Sep; 34(3):453-77. PubMed ID: 25168937 [TBL] [Abstract][Full Text] [Related]
52. Oral anticoagulants. Winter JH; Douglas AS Clin Haematol; 1981 Jun; 10(2):459-80. PubMed ID: 7032784 [No Abstract] [Full Text] [Related]
53. Monitoring of anticoagulant therapy in cancer patients with thrombosis and the usefulness of blood activation markers. Amiral J; Seghatchian J Transfus Apher Sci; 2017 Jun; 56(3):279-286. PubMed ID: 28552490 [TBL] [Abstract][Full Text] [Related]
54. [Anticoagulant therapy in cardiovascular diseases. II. Clinical problems of anticoagulant therapy]. Latallo ZS; Malanowicz W Kardiol Pol; 1971; 14(1):99-107. PubMed ID: 5552716 [No Abstract] [Full Text] [Related]
55. [Evaluation of a new chromogenic method for measuring prothrombin time in the control of oral anticoagulant therapy]. Colla G; Corciulo G Boll Soc Ital Biol Sper; 1984 Nov; 60(11):2025-31. PubMed ID: 6525255 [TBL] [Abstract][Full Text] [Related]
56. Long-term oral anticoagulant therapy: update on indications, therapeutic ranges, and monitoring. Raj G; Kumar R; McKinney WP Am J Med Sci; 1994 Feb; 307(2):128-32. PubMed ID: 8141139 [TBL] [Abstract][Full Text] [Related]
57. Direct Oral Anticoagulants: Monitoring Anticoagulant Effect. Konkle BA Hematol Oncol Clin North Am; 2016 Oct; 30(5):995-1006. PubMed ID: 27637303 [TBL] [Abstract][Full Text] [Related]
58. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Haematologica; 1985; 70(3):269-70. PubMed ID: 3932161 [No Abstract] [Full Text] [Related]
59. [Administration of acetylsalicylic acid in patients under long-term oral anticoagulant therapy]. Barth P; Walter E; Weber E Verh Dtsch Ges Inn Med; 1972; 78():723-6. PubMed ID: 4579268 [No Abstract] [Full Text] [Related]
60. Anticoagulant and antiplatelet medications. Chevoya L; Housholder-Hughes S Crit Care Nurse; 2006 Jun; 26(3):19-20; author reply 19-20. PubMed ID: 16717382 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]